NCT01610336 2021-04-08
A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment
Novartis
Phase 2 Completed
Novartis
Wake Forest University Health Sciences
National Cancer Institute (NCI)
Massachusetts General Hospital
National Cancer Institute (NCI)
Swiss Cancer Institute